reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Autolus Therapeutics plc

AUTL · Nasdaq

1 reporting failure in the last 12 months

Companies at this level ended the following year delisted, bankrupt, restated or silent 9.2% of the time, against 4.0% for companies with a clean record.

$549Mpublic float
2026-04-16most recent failure
2024-03-21declared past accounts unreliable

Score over time

0122024202520262024-04-01 · score 12024-03-21 accounts unreliable2024-07-01 · score 22024-05-13 filed late (10-Q) · complex accounting2024-03-21 accounts unreliable2024-10-01 · score 22024-05-13 filed late (10-Q) · complex accounting2024-03-21 accounts unreliable2025-01-01 · score 22024-05-13 filed late (10-Q) · complex accounting2024-03-21 accounts unreliable2025-04-01 · score 12024-05-13 filed late (10-Q) · complex accounting2026-07-01 · score 12026-04-16 auditor change2026-10-01 · score 12026-04-16 auditor change

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Autolus Therapeutics plc (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Q1 2024 10-Q”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period without unreasonable effort or expense. The Company requires additional time to finalize its financial statements for the quarter ended March 31, 2024 to complete certain open technical accounting matters related to: (i) the projected impact of the autoimmune opportunity for the obe-cel program on the Blackstone liability valuation; and (ii) the Company’s collaboration with BioNTech, which signed during the quarter ended March 31, 2024. The Company expects to file its Q1 2024 10-Q with the SEC as soon as practicable, and no later than the fifth calendar day following the prescribed due date, in accordance with Rule 12b-25

NT 10-Q, filed 2024-05-13 · complex accounting

What it filed

2026-04-16auditor changed or resigned SEC →

2024-05-13filed late (10-Q)complex accounting SEC →

Autolus Therapeutics plc (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Q1 2024 10-Q”) with the Securities and Exchange Commission (“SEC”) within the prescribed time period without unreasonable effort or expense. The Company requires additional time to finalize its financial statements for the quarter ended March 31, 2024 to complete certain open technical accounting matters related to: (i) the projected impact of the autoimmune opportunity for the obe-cel program on the Blackstone liability valuation; and (ii) the Company’s collaboration with BioNTech, which signed during the quarter ended March 31, 2024. The Company expects to file its Q1 2024 10-Q with the SEC as soon as practicable, and no later than the fifth calendar day following the prescribed due date, in accordance with Rule 12b-25

2024-03-21accounts declared unreliable SEC →

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com